Necroptotic cell death consequences and disease relevance

Area of Science:

• Cellular Biology
• Immunology
• Pathology

Background:

• Cell death research has revealed genetically encoded pathways beyond apoptosis.
• Necrosis encompasses distinct modalities like pyroptosis, necroptosis, and ferroptosis.
• Targeting cell death pathways offers potential therapeutic strategies for inflammatory diseases.

Purpose of the Study:

• To review the evidence for targeting necroptosis, a specific form of programmed necrosis.
• To examine the expression of necroptosis machinery in human organs and cell types.
• To assess the role of necroptosis in human diseases and its therapeutic potential.

Main Methods:

• Review of molecular, structural, and disease-relevant findings on necroptosis.
• Identification of key molecular players (ZBP1, RIPK1, RIPK3, MLKL) in human necroptosis.
• Analysis of immunogenic consequences and disease association of necroptosis.

Main Results:

• A specific necroptotic signature involving ZBP1, RIPK1, RIPK3, and MLKL is identified in human lymphocytes.
• Evidence suggests necroptosis is active in humans and can be triggered by ischemic injuries.
• Mouse studies show limitations due to differences with the human necroptotic apparatus.

Conclusions:

• Necroptosis is a distinct, genetically encoded cell death pathway with significant implications for human health.
• Targeting necroptosis holds promise for treating inflammatory diseases and preventing tissue damage.
• Further research is needed to overcome limitations in mouse models and fully elucidate necroptosis's clinical relevance.